Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-038 in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982Phase 2Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Multispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emfizatamab in non-Hodgkin lymphoma (NHL), sponsored by Biokin Pharmaceutical. Started Sep 2022; status: recruiting.
02
Drugs
emfizatamab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05623982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05623982.